marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-12-2024
Citius Pharmaceuticals Balance Sheet 2011-2024 | CTXR
Annual Balance Sheet Citius Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-26 M | -41 M | -69.2 M | -13.5 M | -7.72 M | -9.01 M | -3.03 M | 379 K | -676 K | -952 K | 3.21 K | 16.9 K | 18.3 K |
Long Term Debt |
263 K | 481 K | 678 K | 165 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
218 K | 197 K | 177 K | 159 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 6.01 M | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
5.78 M | 4.53 M | 3.98 M | 4.1 M | 4.61 M | 3.18 M | 2.47 M | 5.18 M | 1.38 M | 2.3 M | 14.7 K | 46 K | 24.1 K |
Total Liabilities |
12.2 M | 10.6 M | 9.65 M | 10.1 M | 4.61 M | 3.18 M | 2.47 M | 5.18 M | 1.38 M | 2.3 M | 14.7 K | 46 K | 24.1 K |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-162 M | -130 M | -96 M | -70.6 M | -55.8 M | -40.3 M | -27.7 M | -17.3 M | -9.04 M | -6.14 M | -95.2 K | -63.8 K | -41.8 K |
Total Assets |
104 M | 114 M | 142 M | 43.8 M | 29 M | 31.1 M | 24.4 M | 22 M | 742 K | 1.56 M | - | 135 | 212 |
Cash and Cash Equivalents |
26.5 M | 41.7 M | 70.1 M | 13.9 M | 7.89 M | 9.18 M | 3.2 M | 294 K | 676 K | 1.55 M | 54.4 K | 41.7 K | 212 |
Book Value |
91.4 M | 103 M | 133 M | 33.7 M | 24.4 M | 27.9 M | 21.9 M | 16.8 M | -635 K | -742 K | -14.7 K | -45.8 K | -23.8 K |
Total Shareholders Equity |
90.8 M | 103 M | 132 M | 33.7 M | 24.4 M | 27.9 M | 21.9 M | 16.8 M | -635 K | -742 K | -2.9 M | -1.61 M | -23.8 K |
All numbers in USD currency
Quarterly Balance Sheet Citius Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
84.4 K | 145 K | 205 K | 263 K | 320 K | 375 K | 429 K | 481 K | 533 K | 582 K | 631 K | 678 K | 725 K | 678 K | 813 K | 855 K | 855 K | 855 K | 976 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
10.8 M | 10.7 M | 12.1 M | 12.2 M | 12.1 M | 12.4 M | 10.7 M | 10.6 M | 9.98 M | 9.59 M | 13 M | 9.65 M | 9.31 M | 9.65 M | 9.51 M | 10.1 M | 10.1 M | 10.1 M | 4.61 M | 9.59 M | 4.61 M | 4.61 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.3 M | - | - | 3.01 M | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-191 M | -180 M | -171 M | -162 M | -152 M | -144 M | -133 M | -130 M | -122 M | -113 M | -105 M | -96 M | -91.1 M | -96 M | -81.1 M | -70.6 M | -70.6 M | -70.6 M | -60.1 M | -53 M | -55.8 M | -55.8 M | -44.1 M | -40.3 M | -40.3 M | -40.3 M | -31 M | -27.7 M | -27.7 M | -27.7 M | -19.5 M | -17.3 M | -17.3 M | -17.3 M | -10.3 M | -9.04 M | -9.04 M | -9.04 M | -6.96 M | -6.14 M | -6.14 M | -6.14 M | -5.4 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
97.1 M | 90.7 M | 97.4 M | 104 M | 110 M | 104 M | 112 M | 114 M | 120 M | 128 M | 138 M | 142 M | 147 M | 142 M | 35.3 M | 43.8 M | 43.8 M | 43.8 M | 25 M | 36.7 M | 29 M | 29 M | 28.1 M | 31.1 M | 31.1 M | 31.1 M | 28.5 M | 24.4 M | 24.4 M | 24.4 M | 21.5 M | 22 M | 22 M | 22 M | 347 K | 742 K | 742 K | 742 K | 823 K | 1.56 M | 1.56 M | 1.56 M | 108 K | - | - | 5.95 K | 99 | 135 | 135 | 135 | 216 | 212 | 212 | 212 |
Cash and Cash Equivalents |
17.9 M | 12.6 M | 20.3 M | 26.5 M | 33.3 M | 29.1 M | 36.9 M | 41.7 M | 48 M | 55.8 M | 65.4 M | 70.1 M | 116 M | 70.1 M | 4.3 M | 13.9 M | 13.9 M | 4.3 M | 2.78 M | 7.89 M | 7.89 M | 2.78 M | 7.04 M | 9.18 M | 9.18 M | 7.04 M | 7.37 M | 3.2 M | 3.2 M | 7.37 M | 46.8 K | 294 K | 294 K | 46.8 K | 281 K | 676 K | 676 K | 281 K | 817 K | 1.55 M | 1.55 M | 817 K | 54.4 K | 1.27 K | - | - | 41.7 K | 135 | 135 | 99 | 61.5 K | 212 | 212 | 216 |
Book Value |
86.3 M | 80 M | 85.3 M | 91.4 M | 98.3 M | 91.8 M | 101 M | 103 M | 110 M | 118 M | 125 M | 133 M | 137 M | 133 M | 25.8 M | 33.7 M | 33.7 M | 33.7 M | 20.4 M | 27.2 M | 24.4 M | 24.4 M | 28.1 M | 31.1 M | 31.1 M | 31.1 M | 28.5 M | 24.4 M | 24.4 M | 24.4 M | 21.5 M | 22 M | 22 M | 22 M | 347 K | 742 K | 742 K | 742 K | 823 K | -742 K | 1.56 M | 1.56 M | -2.9 M | - | - | 5.95 K | 99 | 135 | 135 | 135 | 216 | 212 | 212 | 212 |
Total Shareholders Equity |
85.7 M | 79.4 M | 84.7 M | 90.8 M | 98.3 K | 91.8 M | 101 M | 103 M | 110 M | 118 M | 125 M | 132 M | 137 M | 126 M | 25.8 M | 33.7 M | 33.7 M | 25.2 M | 23.2 M | 27.2 M | 20.4 M | 20.4 M | 27 M | 24.2 M | 24.2 M | 24.2 M | 25.9 M | 21.9 M | 21.9 M | 25.9 M | 15.2 M | 16.8 M | 16.8 M | 16.8 M | -1.59 M | -635 K | -635 K | -635 K | -824 K | -742 K | -742 K | -742 K | -2.9 M | -14.7 K | -14.7 K | -15 K | -1.61 M | -45.8 K | -45.8 K | -47.3 K | -1.06 M | -23.8 K | -23.8 K | -26.4 K |
All numbers in USD currency